Protein biomarkers have a broad range of applications, from the diagnosis, prognosis and monitoring of disease progression to the monitoring of clinical responses to a therapeutic intervention and the development and delivery of personalized treatments. Existing discovery tools have limitations, and the most promising technology, high-content antibody microarrays have not yet reached the proteome-wide scale required in order to become the gold standard discovery tool.
CDI delivers today the highly desirable
As a by-product of the EnigMAb™ platform,
Contact us to discuss how we can put the power of EnigMAb™ biomarker discovery platform at your service.
Click image to enlarge.